Turning scientific progress into value for patients
First written in FY2016. 10 of 12 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2025: 1 of 7 companies on the "Worse" side.
9 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「Building on this strong organizational foundation, we will achieve sustainable growth guided by our “Values and Behaviors in the Organization,” while working to realize our VISION of “be[ing] at the forefront of changing healthcare and turn[ing] scientific progress into ‘value’ for patients.”」
Management Plan 2026 also upholds the VISION of turning scientific progress into value for patients as its basic direction. - FY2025RestatedAnnual report
「To realize our VISION of “be[ing] at the forefront of changing healthcare and turn[ing] scientific progress into ‘value’ for patients,” we formulated Management Plan 2021, covering the five years through fiscal 2025.」
Continues to uphold the VISION and Management Plan 2021 as the basic policy of turning scientific progress into value for patients. - FY2024RestatedAnnual report
「To realize our VISION of “be[ing] at the forefront of changing healthcare and turn[ing] scientific progress into ‘value’ for patients,” we formulated Management Plan 2021, covering the five years through fiscal 2025.」
Continues to uphold the basic direction of turning scientific progress into value for patients in pursuit of the VISION and Management Plan 2021. - FY2024-Q3RestatedAnnual report
「We aim to become a leading “value”-driven life sciences innovator by realizing our VISION: “be at the forefront of changing healthcare and turn scientific progress into ‘value’ for patients.”」
Continues to uphold the direction of turning scientific progress into value for patients as its VISION. - FY2022ReframedAnnual report
「We established a consistent definition of the “value” we provide to patients. The defined “value” is the clinical outcome that is truly important to patients, such as the outcome of treatment, divided by the cost borne by the healthcare system to provide it.」
Defined the patient value previously set out in the VISION as clinical outcomes divided by the cost borne by the healthcare system, and adopted this definition consistently across the company. - FY2021RestatedAnnual report
「We have adopted “be at the forefront of changing healthcare and turn scientific progress into value for patients” as our VISION. We will continue pursuing cutting-edge science and creating healthcare solutions that deliver “value” to patients.」
Continues to uphold the VISION of turning scientific progress into value for patients as a fundamental management policy. - FY2019RestatedAnnual report
「In the VISION formulated in 2015, we declared our commitment to “be at the forefront of changing healthcare and turn scientific progress into value for patients.”」
Continues to uphold the VISION of turning scientific progress into value for patients as the foundation for implementing Management Plan 2018. - FY2018RestatedAnnual report
「Centered on the innovative medicines business in which we have particular strengths, we will continue working to “be at the forefront of changing healthcare and turn scientific progress into value for patients.”」
Continues to uphold the VISION of turning scientific progress into value for patients, centered on the innovative medicines business. - FY2017RestatedAnnual report
「Centered on the innovative medicines business in which we have particular strengths, we will continue working to “be at the forefront of changing healthcare and turn scientific progress into value for patients.”」
Continues to uphold the basic policy of connecting scientific progress with value for patients, centered on the innovative medicines business. - FY2016First statedAnnual report
「Centered on the innovative medicines business in which we have particular strengths, we will continue working to “be at the forefront of changing healthcare and turn scientific progress into value for patients.”」
Sets out the basic direction of connecting the forefront of healthcare with value for patients, centered on the innovative medicines business.